Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices

Journal of the Neurological Sciences

Volumn 344, Issue 1-2, 2014, Pages 80-87

  Wilson, Leslie ^a   Loucks, Aimee ^a   Bui, Christine ^a   Gipson, Greg ^a   Zhong, Lixian ^a   Schwartzburg, Amy ^a   Crabtree, Elizabeth ^b   Goodin, Douglas ^b   Waubant, Emmanuelle ^a   McCulloch, Charles ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Multiple Sclerosis Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Conjoint analysis; Decision aids; Multiple sclerosis; Preference sensitive care; Risk benefit trade offs; Utility

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; RELAPSE; RISK BENEFIT ANALYSIS; DECISION MAKING; DISABILITY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSIOLOGY; PSYCHOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; DECISION MAKING; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PATIENT PREFERENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84906793845     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.06.030     Document Type: Article

References (39)

1. S. Simpson Jr., L. Blizzard, P. Otahal, I. VanderMei, and B. Taylor Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis J Neurol Neurosurg Psychiatry 82 10 2011 1131 1141
2. R. Milo, and E. Kahana Multiple sclerosis: geoepidemiology, genetics and the environment Autoimmun Rev 9 5 2010 A387 A394
3. J.H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B.G. Weinshenker Multiple sclerosis N Engl J Med 343 13 2000 938 952
4. A. Lugaresi, M. de Ioia, D. Travaglini, E. Pietrolongo, E. Pucci, and M. Onofrj Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis Neuropsychiatr. Dis. Treat. 9 2013 893 914
5. N. Wu, S. Minden, D. Hoaglin, L. Hadden, and D. Frankel Quality of life in people with multiple sclerosis: data from the Sonya Slifka longitudinal multiple sclerosis study J Health Hum Serv Adm 30 3 2007 233 267
6. A. Compston, and A. Coles Multiple sclerosis Lancet 372 9648 2008 1502 1517
7. P. Flachenecker, and P. Rieckmann Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 63 15 2003 1525 1533
8. D. Goodin, E. Frohman, and G. Garmany Jr. et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology 58 2 2002 169 178
9. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 9 2006 899 910
10. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, and P. Calabresi et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 5 2010 387 401
11. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group Neurology 43 4 1993 655 661
12. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, and A.M. Salazar et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 3 1996 285 294
13. K.P. Johnson, B.R. Brooks, J.A. Cohen, C.C. Ford, J. Goldstein, and R.P. Lisak et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 7 1995 1268 1276
14. J. Palace Partnership and consent in MS treatment choice J. Neurol. Sci. 335 1 2013 5 8
15. M. Barry, and S. Edgman-Levitan Shared decision making - the pinnacle of patient-centered care N Engl J Med 366 2012 780 781
16. J. Hibbard, and J. Greene What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs Health Aff 32 2 2013 207 214
17. C. Heesen, A. Solari, A. Giordano, J. Kasper, and S. Kopke Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement J. Neurol. Sci. 306 1 2011 192 197
18. G. Elwyn, P. Kinersley, and R. Grol Shared decision making and the concept of equipose; the competencies of involving patients in healthcare choices Br. J. Gen. Pract. 50 2000 892 897
19. M. Ryan, and S. Farrar Using conjoint analysis to elicit preferences for health care BMJ 320 7248 2000 1530 1533
20. A. Stiggelbout, and J.C.J.M. de Haes Patient preference for cancer therapy: an overview of measurement approaches J Clin Oncol 19 1 2001 220 230
21. B. Orme Getting started with conjoint analysis 2nd ed. 2008 Research Publishers LLC Madison, Wisconsin
22. J. Bridges, E. Onukwugha, and F. Johnson et al. Patient preference methods - a patient centered evaluation paradigm ISPOR Connect 13 2007 4 7
23. J. Bridges, A. Hauber, D. Marshal, A. Lloyd, L. Prosser, and D. Regier et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR good research practices for conjoint analysis task force Value Health 14 2011 403 413
24. S. Szeinbach, S. Harpe, T. Flynn, A. Lloyd, J. Bridges, and A. Muhlbacher et al. Understanding Conjoint Analysis applications in health. ISPOR Connections http://www.ispor.org/news/articles/jan-feb2011/understanding- conjoint-analysis.asp 2011 [accessed February, 2014]
25. G. Van Houtven, F. Johnson, V. Kilambi, and A. Hauber Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis Med Decis Making 31 3 2011 469 480
26. A. Hauber, F. Johnson, and E. Andrews Risk-benefit analysis methods for pharmaceutical decision-making - where are we now? ISPOR Connect 12 6 2006 3 5
27. L. Wilson, A. Loucks, G. Gipson, L. Zhong, C. Bui, and E. Miller et al. Patient preferences for attributes of disease modifying multiple sclerosis therapies: development and results of a ratings based conjoint analysis Int J MS Care 2014 [Accepted February, 2014]
28. Sawtooth Software I http://www.sawtoothsoftware.com 2012 [801-477-4700, Orem, UT., accessed February, 2014]
29. I. Sawtooth Software The CBC system for choice-based conjoint analysis Technical Paper Series Version 8 2013 1 27 [Orem, Utah]
30. K. Chrzan, and B. Orme Research paper series: an overview and comparison of design strategies for choice-based conjoint analysis. Sawtooth Software, Inc Sequim, WA http://www.sawtoothsoftware.com 2000 [accessed February, 2014]
31. A. Hauber, N. Arden, A. Mohamed, F. Johnson, P. Peloso, and D. Watson et al. A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis Osteoarthritis Cartilage 21 2 2013 289 297
32. G. Bloomgren, S. Richman, and C. Hotermans et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy N Engl J Med 20 266 2012 1870 1880
33. K. Samson Health officials launch investigation in deaths of patients taking fingolimod Neurol Today 12 4 2012 27 28
34. B. Ramkumar, M. Chadha, and M. Barcos et al. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis Cancer Genet Cytogenet 182 2 2008 126 129
35. F. Johnson, G. Van Houtven, and S. Ozdemir et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy J Neurol 256 4 2009 554 562
36. V. Devonshire, Y. Lapierre, R. Macdonell, C. Ramo-Tello, F. Patti, and P. Fontoura et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis Eur J Neurol 18 2011 69 77
37. J. O'Brian, A. Ward, and A. Patrick et al. Cost of managing an episode of relapse in multiple sclerosis in the United States BMC Health Serv Res 12 2003 1 12
38. S. Ramagopalan, and A. Sadovnick Epidemiology of multiple sclerosis Neurol Clin 29 2 2011 207 217
39. C. Confavreux, and S. Vukusic The clinical epidemiology of multiple sclerosis Neuroimaging Clin N Am 18 4 2008 589 622